BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to 2 From 4 - Marketscreener.com
CYTDelisted Stock | USD 2.76 0.01 0.36% |
Slightly above 54% of Cyteir Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Cyteir Therapeutics suggests that many traders are impartial regarding Cyteir Therapeutics' prospects. Cyteir Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cyteir Therapeutics' earnings reports, geopolitical events, and overall market trends.
Cyteir |
BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to 2 From 4 Marketscreener.com
Read at news.google.com
Cyteir Therapeutics Fundamental Analysis
We analyze Cyteir Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Cyteir Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Cyteir Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyteir Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics with similar companies.
Peers
Cyteir Therapeutics Related Equities
MNOV | MediciNova | 6.63 | ||||
CSBR | Champions Oncology | 5.97 | ||||
NUVB | Nuvation Bio | 4.53 | ||||
RZLT | Rezolute | 3.95 | ||||
HCWB | HCW Biologics | 2.38 | ||||
NKTX | Nkarta | 2.02 | ||||
CCCC | C4 Therapeutics | 0.81 | ||||
LYEL | Lyell Immunopharma | 0.72 | ||||
MOLN | Molecular Partners | 0.57 | ||||
GBIO | Generation Bio | 0.34 | ||||
FHTX | Foghorn Therapeutics | 0.23 | ||||
SANA | Sana Biotechnology | 0.29 | ||||
GLUE | Monte Rosa | 0.54 | ||||
ANEB | Anebulo Pharmaceuticals | 1.86 | ||||
PRLD | Prelude Therapeutics | 2.56 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |